Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Rudich SM et al. | Immunosuppression using tacrolimus, mycophenolate, and prednisone following orthotopic liver transplantation: a single-center experience. | 1998 | Transplant. Proc. | pmid:9636574 |
Ringe B et al. | Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept. | 1998 | Transplant. Proc. | pmid:9636573 |
Cai TH et al. | Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation. | 1998 | Transplant. Proc. | pmid:9636572 |
Taibi A et al. | Rescue FK506 therapy for acute rejection and early chronic rejection after liver transplantation: report of 14 cases. | 1998 | Transplant. Proc. | pmid:9636571 |
Platz KP et al. | FK506 for primary and rescue therapy following liver transplantation. | 1998 | Transplant. Proc. | pmid:9636570 |
Millis JM et al. | Successful use of tacrolimus for initial rejection episodes after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636569 |
Zervos XA et al. | Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636568 |
Jain A et al. | Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. | 1998 | Transplant. Proc. | pmid:9636567 |
Van Buren D et al. | Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus). | 1998 | Transplant. Proc. | pmid:9636566 |
Wiesner RH | Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. | 1998 | Transplant. Proc. | pmid:9636565 |
McDiarmid S et al. | One hundred children treated with tacrolimus after primary orthotopic liver transplantation. | 1998 | Transplant. Proc. | pmid:9636564 |
Samuel D et al. | Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation. | 1998 | Transplant. Proc. | pmid:9636563 |
Rossi G et al. | Three-year follow-up of low dose tacrolimus oral therapy after liver transplantation: a single-centre experience. | 1998 | Transplant. Proc. | pmid:9636562 |
Grewal HP et al. | Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. | 1998 | Transplant. Proc. | pmid:9636558 |
Shapiro R et al. | Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. | 1998 | Transplant. Proc. | pmid:9636557 |
Fitzsimmons WE et al. | Demographic considerations in tacrolimus pharmacokinetics. | 1998 | Transplant. Proc. | pmid:9636552 |
Neylan JF | Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. | 1998 | Transplant. Proc. | pmid:9636551 |
Kumar MS et al. | ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. | 1998 | Transplant. Proc. | pmid:9636549 |
Undre NA et al. | Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. | 1998 | Transplant. Proc. | pmid:9636527 |
Woodle ES et al. | Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group. | 1998 | Transplant. Proc. | pmid:9636526 |